AUDUBON, Pa., Jan. 05, 2017 -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, today announced that the Excelsius GPS™, a revolutionary system providing robotic trajectory guidance and navigation, is now CE marked. This platform technology supports both minimally invasive and open orthopedic and neurosurgical procedures, with applications ranging from the cervical spine to the sacroilium, long bones and cranium. Excelsius GPS™ seamlessly integrates with Globus Medical implants and instruments and is compatible with pre-operative CT, intra-operative CT and fluoroscopic imaging modalities. The system is designed to minimize radiation exposure, streamline workflow, and reproducibly assist in implant placement.
“Excelsius GPSTM is another example of continued innovation from Globus Medical, utilizing feedback from expert surgeons from different specialties,” said Norbert Johnson, Vice President of Robotics, Imaging, & Navigation. “Our goal with the Excelsius GPS™ System is to improve the continuum of care for patients, surgeons, and hospitals through the application of robotic and navigation technology in the fields of spine, trauma, and cranial surgery.”
About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to successfully integrate the international operations acquired from Alphatec, both in general and on our anticipated timeline, our ability to transition Alphatec’s international customers to Globus Medical products, our ability to realize the expected benefits to our results from the Alphatec acquisition, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
Daniel Scavilla Senior Vice President, Chief Financial Officer Phone: (610) 930-1800 Email: [email protected] www.globusmedical.com


TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 



